Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis

(2014) Pranabashis Haldar et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

EAACI position statement on asthma exacerbations and severe asthma

(2013) A. Custovic et al.   ALLERGY

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

(2013) K. F. Chung et al.   EUROPEAN RESPIRATORY JOURNAL

Strong control over multiple endpoints: are we adding value to the assessment of medicines?

(2013) Andrew Stone et al.   PHARMACEUTICAL STATISTICS

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

Asthma phenotypes: the evolution from clinical to molecular approaches

(2012) Sally E Wenzel   NATURE MEDICINE

Risk factors for death in adults with severe asthma

(2010) Theodore A. Omachi et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations

(2009) Helen K. Reddel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

(2009) Pranabashis Haldar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

(2009) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited

(2008) O. N. Keene et al.   EUROPEAN RESPIRATORY JOURNAL